Investment Thesis
Acurx is a pre-revenue pharmaceutical development-stage company with no commercial sales and negative operating cash flows, dependent entirely on existing capital reserves. While the balance sheet shows reasonable liquidity with $9.3M cash and zero debt, the company faces extreme execution risk with an estimated 2-year cash runway at current burn rates. Investment viability is entirely contingent on successful clinical outcomes with no near-term revenue visibility.
Strengths
- Strong balance sheet composition with 98% of assets in cash
- Zero debt burden and favorable 2.44x current ratio provide runway
- Modest insider activity suggests management engagement
Risks
- No revenue generation - completely pre-commercial stage
- Negative cash burn of $1.4M per quarter erodes capital base
- Extreme pharma development risk with uncertain clinical outcomes
- Limited runway of ~2 years at current burn rate
- Highly dilutive capital requirements likely needed for continued operations
Key Metrics to Watch
- Operating cash burn rate and cash runway extension
- Clinical trial progress and regulatory milestones
- Equity raises and dilution impact on shareholder base
Financial Metrics
Revenue
N/A
Net Income
-1.7M
EPS (Diluted)
$-0.62
Free Cash Flow
-1.4M
Total Assets
9.5M
Cash
9.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-24.0%
ROA
-17.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.44x
Quick Ratio
2.44x
Debt/Equity
0.00x
Debt/Assets
26.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T07:46:23.577670 |
Data as of: 2026-03-31 |
Powered by Claude AI